NEW ORLEANS, LA—A novel transcatheter intracardiac shunt device appears to provide sustained clinical benefit at 1 year in heart failure patients with preserved or only mildly reduced ejection ...

A study of an investigational interatrial shunt for treating high-risk heart failure patients with reduced and preserved ejection fraction suggests the device has a high degree of safety and efficacy, ...

The first implantation of a new device called interatrial shunt device (IASD) is a success. This device is developed by Corvia Medical. The device is a non-surgical device that provides continuous ...

The Interatrial shunt is intended for insignificantly obtrusive delivery to the heart using trans catheter systems. The dime-sized gadget is embedded into the septal wall between the atrial chambers, ...

ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

Please provide your email address to receive an email when new articles are posted on . Physiologic aqueous outflow pathways include the conventional outflow pathway and the uveoscleral outflow.

NEWARK, Del, Feb. 20, 2024 (GLOBE NEWSWIRE) -- According to Future Market Insights’ latest industry analysis, the Hydrocephalus Shunt Market size is estimated to be around US$ 546.09 million in 2024.

The Business Research Company's Interatrial Shunt Devices Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ONLINE30 – Stay ...

The US Food and Drug Administration (FDA) is warning healthcare providers about potential hazards from interactions between implanted programmable cerebrospinal fluid (CSF) shunts and hearing implants ...